Organogenesis (ORGO) Rating Reiterated by BTIG Research

BTIG Research reiterated their buy rating on shares of Organogenesis (NASDAQ:ORGO) in a report issued on Sunday, AnalystRatings.com reports. BTIG Research currently has a $12.00 price target on the stock.

“We maintain our Buy rating and $12 PT on shares of ORGO following 1Q19 results. ORGO topped expectations across the board, with rev. of $57.1M beating BTIG/Consensus estimates of $50.6M/$52.6M bolstered by strength in PuraPly and Surgical & Sports Medicine (S&SM). FY19 guidance was raised by ~$2M (at the midpoint) ($248M-$259M to $249M-$262M) on the back of improved expectations in Surgical & Sports Medicine ($29.5M- $31.0M to $30M-$33M) and despite mfg. issues related to Affinity. We view guidance as a reflection of conservatism but confidence in underlying business fundamentals from increased rep growth, account growth, and further account penetration.”,” BTIG Research’s analyst wrote.

ORGO has been the topic of several other research reports. SunTrust Banks started coverage on Organogenesis in a report on Thursday, April 11th. They set a buy rating and a $11.00 price objective on the stock. Oppenheimer started coverage on Organogenesis in a report on Wednesday, April 17th. They set an outperform rating and a $11.00 price objective on the stock. CIBC started coverage on Organogenesis in a report on Wednesday, April 17th. They set an outperform rating and a $11.00 price objective on the stock. Finally, Credit Suisse Group started coverage on Organogenesis in a report on Thursday, May 2nd. They set an outperform rating and a $9.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average target price of $10.80.



Organogenesis stock opened at $7.09 on Friday. Organogenesis has a 1-year low of $6.28 and a 1-year high of $310.90.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.05). The business had revenue of $57.12 million during the quarter, compared to the consensus estimate of $55.12 million. Research analysts predict that Organogenesis will post -0.24 EPS for the current year.

Hedge funds have recently modified their holdings of the business. Morgan Stanley purchased a new position in shares of Organogenesis during the first quarter worth about $30,000. Citigroup Inc. purchased a new position in shares of Organogenesis during the first quarter worth about $41,000. Northern Trust Corp purchased a new position in shares of Organogenesis during the first quarter worth about $131,000. California Public Employees Retirement System purchased a new position in shares of Organogenesis during the first quarter worth about $202,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Organogenesis during the first quarter worth about $475,000. 0.08% of the stock is currently owned by institutional investors.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Further Reading: Outstanding Shares and The Effect on Share Price

Analyst Recommendations for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.